Ligand Pharmaceuticals RSS Feed | Nachrichten | finanzen.netwww.finanzen.net bietet Finanznachrichten zum weltweiten Boersengeschehenhttp://www.finanzen.netde-deSmartHouse Media GmbHhttp://finanzen.net/images/finanzen_net.gifFinanzen.nethttp://www.finanzen.netLigand Announces Approval for RevoladeŽ in Europehttp://www.finanzen.net/nachricht/Ligand-Announces-Approval-for-Revolade-in-Europe-756718 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> <b>Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)</b> today announced that GlaxoSmithKline (NYSE: GSK) was granted marketing authorization ...http://www.finanzen.net/nachricht/Ligand-Announces-Approval-for-Revolade-in-Europe-756718Ligand to Present at the Cowen & Company 30th Annual Healthcare Conference on March 11http://www.finanzen.net/nachricht/Ligand-to-Present-at-the-Cowen-Company-30th-Annual-Healthcare-Conference-on-March-11-750151 <b>Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)</b> announced today that President and Chief Executive Officer John L. Higgins, and Vice President of Discovery Research Dr. Martin Meglasson will present at the ...http://www.finanzen.net/nachricht/Ligand-to-Present-at-the-Cowen-Company-30th-Annual-Healthcare-Conference-on-March-11-750151Ligand Announces Fourth Quarter and Full Year 2009 Consolidated Financial Resultshttp://www.finanzen.net/nachricht/Ligand-Announces-Fourth-Quarter-and-Full-Year-2009-Consolidated-Financial-Results-739837 <style type="text/css"> <!-- .bwcellpaddingbottom1 {padding-bottom: 2.0px} .bwcellpaddingbottom3 {padding-bottom: 4.0px} .bwcellpaddingleft0 {padding-left: 0.0px} .bwcellpaddingleft3 {padding-left: 15.0px} .bwcellpaddingleft6 {padding-left: 30.0px} .bwcellpaddingleft9 ...http://www.finanzen.net/nachricht/Ligand-Announces-Fourth-Quarter-and-Full-Year-2009-Consolidated-Financial-Results-739837Ligand to Report Fourth Quarter Results on February 9thhttp://www.finanzen.net/nachricht/Ligand-to-Report-Fourth-Quarter-Results-on-February-9th-735475 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> <b>Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)</b> announced today that its President and Chief Executive Officer, John L. Higgins will ...http://www.finanzen.net/nachricht/Ligand-to-Report-Fourth-Quarter-Results-on-February-9th-735475Ligand Completes Acquisition of Metabasishttp://www.finanzen.net/nachricht/Ligand-Completes-Acquisition-of-Metabasis-734071 <style type="text/css"> <!-- .bwlistitemmarginbottom {margin-bottom: 10.0px} .bwtextaligncenter {text-align: center} .bwunderlinestyle {text-decoration: underline} --> </style> <!-- sh_cad_1 --> <b>Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ...http://www.finanzen.net/nachricht/Ligand-Completes-Acquisition-of-Metabasis-734071Ligand Completes Neurogen Acquisitionhttp://www.finanzen.net/nachricht/Ligand-Completes-Neurogen-Acquisition-720138 <style type="text/css"> <!-- .bwlistitemmarginbottom {margin-bottom: 10.0px} .bwtextaligncenter {text-align: center} .bwunderlinestyle {text-decoration: underline} --> </style> <!-- sh_cad_1 --> <b>Ligand Pharmaceuticals Incorporated (NASDAQ: ...http://www.finanzen.net/nachricht/Ligand-Completes-Neurogen-Acquisition-720138Ligand Announces Positive Regulatory Opinion in Europe for Revolade for Chronic Immune Thrombocytopenic Purpurahttp://www.finanzen.net/nachricht/Ligand-Announces-Positive-Regulatory-Opinion-in-Europe-for-Revolade-for-Chronic-Immune-Thrombocytopenic-Purpura-718282 <style type="text/css"> <!-- .bwcellpaddingleft0 {padding-left: 0.0px} .bwcellpaddingright0 {padding-right: 0.0px} .bwcellparagraphmargin {margin-bottom: 0px; margin-top: 0px} .bwtablebottommargin {margin-bottom: 10.0px} .bwtextaligncenter {text-align: ...http://www.finanzen.net/nachricht/Ligand-Announces-Positive-Regulatory-Opinion-in-Europe-for-Revolade-for-Chronic-Immune-Thrombocytopenic-Purpura-718282Ligand and Neurogen Amend Merger Agreementhttp://www.finanzen.net/nachricht/Ligand-and-Neurogen-Amend-Merger-Agreement-717803 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} .bwunderlinestyle {text-decoration: underline} --> </style> <!-- sh_cad_1 --> <b>Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) </b>and <b>Neurogen Corporation ...http://www.finanzen.net/nachricht/Ligand-and-Neurogen-Amend-Merger-Agreement-717803Ligand and Neurogen Amend Merger Agreementhttp://www.finanzen.net/nachricht/Ligand-and-Neurogen-Amend-Merger-Agreement-717797 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} .bwunderlinestyle {text-decoration: underline} --> </style> <!-- sh_cad_1 --> <b>Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) </b>and <b>Neurogen Corporation ...http://www.finanzen.net/nachricht/Ligand-and-Neurogen-Amend-Merger-Agreement-717797Ligand Presents New Preclinical Data on its Lead SARM Molecule LGD-4033 at the Gerontological Society of America Annual Meetinghttp://www.finanzen.net/nachricht/Ligand-Presents-New-Preclinical-Data-on-its-Lead-SARM-Molecule-LGD-4033-at-the-Gerontological-Society-of-America-Annual-Meeting-705440 <style type="text/css"> <!-- .bwlistitemmarginbottom {margin-bottom: 10.0px} .bwtextaligncenter {text-align: center} --> </style> <b>Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)</b> today announced that data from a preclinical ...http://www.finanzen.net/nachricht/Ligand-Presents-New-Preclinical-Data-on-its-Lead-SARM-Molecule-LGD-4033-at-the-Gerontological-Society-of-America-Annual-Meeting-705440